{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:15Z","timestamp":1790270715295,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5 \\u00D7 1000"],"award-info":[{"award-number":["5 \\u00D7 1000"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.ejca.2020.12.028","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T18:47:21Z","timestamp":1611341241000},"page":"197-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis"],"prefix":"10.1016","volume":"145","author":[{"given":"Angela","family":"Esposito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Bagnardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuele","family":"Frassoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Zagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca M.","family":"Varano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Buccimazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Orsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Venetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Mazzarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.12.028_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2020.12.028_bib2","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.12.028_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bjc.2017.274","article-title":"Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers","volume":"117","author":"Hopkins","year":"2017","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.12.028_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2020.12.028_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11912-016-0539-4","article-title":"The obesity paradox in cancer: a Review","volume":"18","author":"Lennon","year":"2016","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ejca.2020.12.028_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.12.028_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204729","article-title":"Body mass index may predict the response to ipilimumab in metastatic melanoma: an observational multi-centre study","volume":"13","author":"Richtig","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.ejca.2020.12.028_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40425-019-0527-y","article-title":"A multicenter study of body mass index in cancer patients treated with anti-PD-1\/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable","volume":"7","author":"Cortellini","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.12.028_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.annepidem.2014.11.010","article-title":"Estimating population attributable fractions to quantify the health burden of obesity","volume":"25","author":"Flegal","year":"2015","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.ejca.2020.12.028_bib10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejca.2020.12.028_bib11","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1093\/ajcn\/48.6.1351","article-title":"Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations","volume":"48","author":"Kvist","year":"1988","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.ejca.2020.12.028_bib12","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1200\/JCO.2008.19.5081","article-title":"Prospective validation of a prognostic score to improve patient selection for oncology phase I trials","volume":"27","author":"Arkenau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.028_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejca.2017.07.027","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: the Gustave Roussy Immune Score (GRIm-Score)","volume":"84","author":"Bigot","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.12.028_bib14","first-page":"360","article-title":"How to best assess abdominal obesity","volume":"21","author":"Fang","year":"2018","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.ejca.2020.12.028_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.12.028_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.12.028_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.ejca.2020.12.028_bib18","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.028_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2017.12.019","article-title":"Cancer, obesity and immunometabolism - connecting the dots","volume":"417","author":"Dyck","year":"2018","journal-title":"Canc Lett"},{"key":"10.1016\/j.ejca.2020.12.028_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001403","article-title":"Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression >\/= 50%: a multicenter study with external validation","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.12.028_bib21","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","article-title":"Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy","volume":"6","author":"Incio","year":"2016","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejca.2020.12.028_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.12.028_bib23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/cncr.32576","article-title":"Adiposity may predict survival in patients with advanced stage cancer treated with immunotherapy in phase 1 clinical trials","volume":"126","author":"Martini","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.12.028_bib24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12916-019-1326-5","article-title":"Recent advances in triple negative breast cancer: the immunotherapy era","volume":"17","author":"Marra","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.ejca.2020.12.028_bib25","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.19.00508","article-title":"Immunotherapy in ovarian cancer: are we there yet?","volume":"37","author":"Kandalaft","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.12.028_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jclinepi.2015.04.005","article-title":"Prediction models need appropriate internal, internal-external, and external validation","volume":"69","author":"Steyerberg","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ejca.2020.12.028_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s40425-016-0178-1","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: volume I - pre-analytical and analytical validation","volume":"4","author":"Masucci","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.12.028_bib28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40425-016-0179-0","article-title":"Validation of biomarkers to predict response to immunotherapy in cancer: volume II - clinical validation and regulatory considerations","volume":"4","author":"Dobbin","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.12.028_bib29","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/bjc.2017.149","article-title":"Subcutaneous adiposity is an independent predictor of mortality in cancer patients","volume":"117","author":"Ebadi","year":"2017","journal-title":"Br J Canc"},{"key":"10.1016\/j.ejca.2020.12.028_bib30","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1158\/0008-5472.CAN-17-3287","article-title":"The importance of body composition in explaining the overweight paradox in cancer-counterpoint","volume":"78","author":"Caan","year":"2018","journal-title":"Canc Res"},{"key":"10.1016\/j.ejca.2020.12.028_bib31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.cmet.2013.05.008","article-title":"Immunological goings-on in visceral adipose tissue","volume":"17","author":"Mathis","year":"2013","journal-title":"Cell Metabol"},{"key":"10.1016\/j.ejca.2020.12.028_bib32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41523-020-0156-0","article-title":"Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer","volume":"6","author":"Kos","year":"2020","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.ejca.2020.12.028_bib33","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/CCI.19.00126","article-title":"Deep-learning\u2013based characterization of tumor-infiltrating lymphocytes in breast cancers from histopathology images and multiomics data","author":"Lu","year":"2020","journal-title":"JCO Clinical Cancer Informatics"},{"key":"10.1016\/j.ejca.2020.12.028_bib34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1479-5876-10-205","article-title":"Cancer classification using the Immunoscore: a worldwide task force","volume":"10","author":"Galon","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2020.12.028_bib35","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","article-title":"Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer","volume":"39","author":"Bindea","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.ejca.2020.12.028_bib36","doi-asserted-by":"crossref","first-page":"e1732","DOI":"10.1634\/theoncologist.2020-0518","article-title":"Pretreatment blood parameters predict efficacy from immunotherapy agents in early phase clinical trials","volume":"25","author":"Criscitiello","year":"2020","journal-title":"Oncol"},{"key":"10.1016\/j.ejca.2020.12.028_bib37","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejca.2020.08.026","article-title":"Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents","volume":"139","author":"Tarantino","year":"2020","journal-title":"Eur J Canc"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2025.116107","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920314532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:22:45Z","timestamp":1778782965000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920314532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":37,"alternative-id":["S0959804920314532"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.028","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.12.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}